Feb 6, 2026 06:17AM
Dec 8, 2025 06:42PM
Dec 8, 2025 04:52PM
Dec 8, 2025 04:40PM
Dec 4, 2025 02:13AM
Nov 18, 2025 07:02PM
Nov 13, 2025 06:50PM Leqembi® approved for IV maintenance treatment in the United Kingdom
Nov 10, 2025 02:16AM
Oct 26, 2025 10:56PM
Sep 2, 2025 11:01PM
Aug 25, 2025 03:26AM
Jul 30, 2025 10:54PM
May 15, 2025 04:56AM
May 8, 2025 07:49AM Exidavnemab phase 2a study expanded to include MSA patients
Apr 1, 2025 06:14AM
Mar 25, 2025 03:08AM
Mar 17, 2025 01:49PM
Mar 3, 2025 03:17AM
Feb 28, 2025 08:11AM
Feb 18, 2025 02:13AM
Jan 31, 2025 07:12AM Update on regulatory review of lecanemab for treatment of early Alzheimer's disease in the European Union
Jan 26, 2025 09:50PM
Jan 13, 2025 09:49PM
Dec 4, 2024 09:44PM
Nov 27, 2024 09:47PM
Nov 14, 2024 12:00PM
Oct 31, 2024 07:43PM
Aug 13, 2024 10:42PM Leqembi approved for the treatment of Alzheimer's disease in the United Arab Emirates
Aug 1, 2024 07:09AM
Jul 30, 2024 05:19PM
Jul 26, 2024 07:49AM
Jul 26, 2024 06:59AM
Jul 23, 2024 02:42AM
Jul 11, 2024 10:59PM
Jul 10, 2024 10:51PM Leqembi approved for the treatment of Alzheimer's disease in Hong Kong
Jun 27, 2024 10:48PM
Jun 9, 2024 10:55PM
May 14, 2024 10:52PM
Mar 31, 2024 11:19PM
Mar 11, 2024 03:18AM
Jan 11, 2024 01:16AM
Jan 9, 2024 03:41AM Leqembi® approved for the treatment of Alzheimer's disease in China
Dec 12, 2023 09:49PM
Nov 13, 2023 03:33AM
Nov 10, 2023 02:47AM
Nov 7, 2023 03:36AM
Nov 6, 2023 11:16PM
Oct 30, 2023 04:01AM
Oct 25, 2023 08:40PM New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD
Oct 24, 2023 11:04AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All